Lv5
860 积分 2021-12-17 加入
Mismatch Repair Deficiency, Microsatellite Instability, and Survival
23小时前
已完结
Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy
15天前
已完结
Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis
15天前
已完结
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
29天前
已完结
The CDCP1 Signaling Hub: A Target for Cancer Detection and Therapeutic Intervention
29天前
已完结
Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment
1个月前
已完结
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
1个月前
已完结
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
1个月前
已完结
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial
1个月前
已完结
Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC)
1个月前
已关闭
皖公网安备34019202002308
